Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-Trial) by Weberschock, T et al.
december 14, 2009 516 Eu  Ro  PE  an JouR  naL of MEd  I  caL RE  SEaRcH
Abstract
Background: there is an unmet medical need for sim-
plified antiretroviral therapy regimens to improve pa-
tient’s compliance and quality of life. the purpose of
this study was to evaluate the efficacy and safety of a
once-daily  regimen  with  tenofovir  (tdf),  Emtric-
itabine (ftc) and nevirapine (nvP) for adult patients
with HIv-1 infection.
Methods: 70 patients were enrolled in a prospective,
multicenter,  non-randomized,  single  arm,  open-label
cohort study. Patients were either na￯ve or had prob-
lems  with  their  current  aRt  and  needed  to  be
changed to another regimen. daily drug dosage was
300 mg tenofovir, 200mg Emtricitabine and 400 mg
nevirapine once daily. follow-up was performed over
72 weeks.
Results: after 72 weeks, the regimen was still contin-
ued  by  52  patients  (74,3%).  of  these,  44  patients
(84,6%)  had  a  viral  load  below  detection  limit.  the
median viral load had decreased by 2,5 log and the me-
dian  cd4  cell  count  had  increased  by  44,8%.  Most
side-effects occurred at an early stage during the study.
Resistances were rare (only two resistances were con-
sidered as newly developed) and occurred rather late
during the study. 
Conclusion: a once-daily regimen of tenofovir, Emtri  -
citabine and nevirapine is an attractive treatment op-
tion since it is safe, effective, and well tolerated.
Key words: nevirapine, tenofovir, Emtricitabine, aRt,
treatment efficacy, once-daily
IntRoductIon
a massive progress in the treatment of HIv infected
patients  has  occurred  in  the  past  decade.  with  the
availability  of  an  increasing  number  of  potent  anti-
retroviral drugs and new treatment groups an effective
anti-retroviral therapy (aRt) has been established. to-
day longterm survival under aRt with high levels of
cd4 t cells seems a realistic aim. However, now that
there are potent anti-retroviral therapies available the
focus of attention has shifted towards improvement
of quality of life. there is still an unmet medical need
for treatment simplification in HIv therapy: conve-
nient and easy therapy regimens are not only needed
to improve quality of life, but also to maintain patient
compliance, which has been shown to be a major fac-
tor  for  long  term  therapeutic  success.  However,  for
any new regimens it is necessary to prove their efficacy
and safety first as measured by reduction of viral load,
improvement of cd4 t cell count and occurrence of
side-effects. 
we  therefore  investigated  the  long-term  efficacy
and tolerability of a simplified therapy regimen with
tenofovir 300mg and Emtricitabine 200mg plus nevi-
rapine 400mg at a once-daily dosage to asses, if this
facilitated therapy scheme is appropriate to provide re-
liable therapeutic effects and a tolerable safety profile.
MEtHodS
PatIEntS
70 patients were enrolled in a multicenter, prospective,
non-randomized, single arm, open-label cohort study
at four outpatient centers in southern germany and
follow-up was performed for 72 weeks. only patients
above 18 years of age with documented HIv1-infec-
tion who were na￯ve for antiretroviral therapy or expe-
riencing side effects with their current aRt regimen
were included in the study. Patients showing nnRtI
resistance or k65R, M41L or L210w mutation were
excluded from the study. Patients gave their written in-
formed consent and the study was conducted in accor-
dance with the declaration of Helsinki.
Study PRotocoL and LaboRatoRy tEStIng
at baseline visit patients were started with tenofovir
300mg, Emtricitabine 200mg and nevirapine 400mg
as once-daily medication.  Study visits were performed
at weeks 0, 2, 4, 6, 12, 24, 36, 48, 60 and 72. viral load,
cd4 and cd8 t cell counts as well as creatinin, got
and gPt serum concentrations were obtained at each
visit.  Plasma  HIv  Rna  levels  were  measured  using
PcR with a lower limit of quantification of 50
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cytometry.  viral  load  modification  and  changes  in
cd4 t cell count were considered as primary outcome
measures.  discontinuation  and  failure  of  follow-up
were considered as treatment failure. 
StatIStIcS
data was checked for gaussian distribution. viral load
data was found not to follow a gaussian distribution,
therefore a kruskal-wallis test was used for statistical
analysis. as post test dunn`s test was used. data of
cd4 t cell counts followed a gaussian distribution,
and consecutively a one-way anova was performed,
followed by bonferroni`s test as post test. In all post
tests data was compared to week 0.
RESuLtS
after 72 weeks, the regimen was still continued by 52
patients (74,3%). 5 patients were lost to follow-up and
14 patients (including one patient lost to follow-up lat-
er on) had to be switched to another regimen because
of  liver  toxicity  (5  patients),  virologic  failure  (4  pa-
tients) elevated serum ck (1 patient) or other causes
(4 patients). 
of the patients continuing the original regimen un-
til week 72, 44 patients (84,6%) had a viral load below
detection limit at that time point; if split up into thera-
py na￯ve and experienced patients, 21 (91,3%) of the
na￯ve patients and 23 (82,1%) of the experienced pa-
tients showed a viral load below detection limit. the
median viral load had decreased by 2,5 log (2,7 log in
the therapy na￯ve group and 1,5 log in the therapy ex-
perienced group). the median cd4 t cell count had
increased  by  44,8%  (from  377,2  cells/ﾵl  to  546,3
cells/ﾵl); by 86,8% in the therapy na￯ve group (from
255 cells/ﾵl to 477 cells/ﾵl) and by 25,7% in the thera-
py  experienced  group  (from  479,8  cells/ﾵl  to  603,0
cells/ﾵl).
of the four patients, which were switched to anoth-
er regimen because of virologic failure, two patients
were switched at week 12 because they did not show
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Table 1. baseline patient characteristics.
total patients 70
Male 53
female 17
Patients with vL > 100.000 12
Patients with vL <50 27
Mean age (years) 41,7 (range 20-72 years)
aRt na￯ve 32
aRt experienced 38
Mean viral load (copies/ml) 76375
aRt na￯ve 161789
aRt experienced 4448
Mean cd4 count (per ﾵl) 377
aRt na￯ve 255
aRt experienced 480
Fig. 1. viral load all patients (during regimen intake).
Fig. 2. viral load therapy na￯ve patients.
Fig. 3. viral load therapy experienced patients.
2. Weberschock_Umbruchvorlage  28.11.09  10:02  Seite 517sufficient  virologic  response  until  this  time  point,
strongly suggesting baseline resistance, which had not
been  detected  during  screening.  the  other  two  pa-
tients had to be switched at a rather late time point (af-
ter 48 weeks) after they had shown reduction of viral
load earlier during the treatment, suggesting the devel-
opment of new resistance(s). 
occurrence  of  side  effects  however  developed
rather early: 3 male and 2 female patients had to be
discontinued because of liver toxicity (after 2, 2, 4, 12,
and 24 weeks). both female patients had baseline cd4
t cell counts above 250 cells/ﾵl (257 and 412 cells/ﾵl)
but all 3 male patients were below 400 cells/ﾵl at the
beginning of the therapy (250, 231 and 296 cells/ﾵl).
one patient was discontinued because of a massively
elevated serum ck at week 2.
dIScuSSIon
there is increasing evidence that the complexity of a
regimen is strongly related to patients’ compliance [1,
2, 3, 4]. this correlation affects a wide population of
HIv positive patients, since it has been shown to be
independent  of  demographic  (race,  ethnicity,  educa-
tion), clinical (most recent cd4 count/ HIv Rna lev-
el, depression) or behavioural (drug use history) influ-
ences [5].
In order to improve patients’ compliance and there-
by increase long time therapy success in a big group of
HIv positive patients new simplified once-daily regi-
mens are needed.
non-nucleoside  reverse  transcriptase  inhibitors
(nnRtIs) seem to be the ideal drugs for simplified
aRt regimens because of their extremely long half-
life which assures high plasma levels over a long time
and thus sustained efficacy in inhibition of viral repro-
duction even during long treatment intervals. 
of the currently licensed nnRtIs only Efavirenz
has  been  approved  for  once-daily  administration.
there is an ongoing discussion of whether nevirapine
might be suitable for once-daily regimens as well. It
has been shown that nevirapine achieves high steady-
state plasma concentrations relative to the concentra-
tion required to inhibit 50% viral replication in vitro
(Ic(50)) and that the daily exposure to nevirapine, as
measured by the plasma concentration over 24 hours
(area under the curve, auc24), as well as half-life and
time to maximal plasma concentration were not signif-
icantly  different  between  the  400mg  once-daily  and
200mg  twice-daily  dose  regimen.  However,  in  the
once-daily group there were higher maximal and lower
minimal plasma concentrations [6, 7]. these findings
were  consistent  with  the  data  acquired  in  the  2nn
study [8], which further analyzed the clinical implica-
tions of these differences in plasma levels. after 48
weeks no differences in treatment failures were found
comparing  the  nevirapine  400mg  once-daily  and
200mg twice-daily regimen [9]. In addition, no statisti-
cally significant differences in treatment failure were
found comparing Efavirenz and nevirapine as once-
or twice-daily regimen. also, no significant differences
in the occurrence of grade 3 and 4 events were found
between these three groups.
Even though these data suggest that nevirapine ap-
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Fig. 4. cd4 count all patients (during regimen intake).
Fig. 5. cd4 count therapy na￯ve patients.
Fig. 6. cd4 count therapy experienced patients.
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pears to be suitable for once-daily regimens, there is
still only few data available about the use of nevirap-
ine in this context. nevertheless there seems to be a
need for a longer follow-up to actually determine the
continuous efficacy of a regimen [10]. very little data
is available about the fixed combination of nevirapine,
tenofovir and Emtricitabine at a once-daily dosage.
we therefore investigated the simplified regimen of
nevirapine  400mg,  tenofovir  300mg  and  Emtricita  -
bine 200mg (each taken once daily) over 72 weeks.
we found that in the long-term assessment the regi-
men was effective and well tolerated. Side-effects were
rare and occurred at a rather early stage: only two pa-
tients (2,9%) had to be discontinued from the regimen
because of side effects after week 4. However, treat-
ment  was  interrupted  in  eight  patients  (11,4%)  be-
cause  of  side-effects  in  the  first  four  weeks.  when
splitting up patients with side-effects, we found gen-
der-specific differences with a higher incidence in the
female study population. thus, these results emphasise
the need for more gender specific investigations of ef-
fectiveness  and  safety  in  certain  HIv  therapy  regi-
mens.
furthermore, only two patients (2,9%) were consid-
ered of having developed new treatment-limiting re-
sistances during 72 weeks. these findings are in con-
trast  with  the  data  of  the  daufIn  study  (zidovu-
dine/lamivudine 300 mg/150 mg plus nevirapine 200
mg  twice  daily  versus  lamivudine  300  mg,  tenofovir
245 mg and nevirapine 400 mg once daily) which was
stopped after early virologic failure in the once-daily
versus  twice-daily  group.  However,  different  back-
bones were used in both groups and the baseline char-
acteristics in the once-daily group indicated a signifi-
cantly higher median viral load and significantly lowed
cd4 t cell count [11], thus explanatory power of the
study findings must certainly be challenged. 
another study revealed that the once-daily dosage
of nevirapine (used with a fixed backbone of Lami  -
vudine and Stavudine) performed even better than the
twice-daily dosage in preventing treatment failure [12].
these data are more consistent with our findings of
only little resistance development during the once-dai-
ly  dosage  of  nevirapine.  nevertheless,  further  re-
search  is  needed  to  investigate  prevention  of  early
treatment failure to increase therapy efficacy and safety.
concLuSIon
nevirapine once-daily, when used with a fixed back-
bone of tenofovir and Emtricitabine, is a very safe
and  effective  regimen,  especially  after  the  initiation
phase. 
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